4//SEC Filing
Vifor (International) Ltd 4
Accession 0000899243-20-018769
CIK 0001340652other
Filed
Jul 7, 8:00 PM ET
Accepted
Jul 8, 8:39 PM ET
Size
29.3 KB
Accession
0000899243-20-018769
Insider Transaction Report
Form 4
Vifor (International) Ltd
10% Owner
Transactions
- Sale
Common Stock, par value $0.001 per share
2020-07-06$57.80/sh−47,825$2,764,118→ 10,541,219 total(indirect: See Footnotes) - Sale
Common Stock, par value $0.001 per share
2020-07-06$59.57/sh−20,379$1,214,024→ 10,502,354 total(indirect: See Footnotes) - Sale
Common Stock, par value $0.001 per share
2020-07-07$59.04/sh−56,790$3,352,728→ 10,443,114 total(indirect: See Footnotes) - Sale
Common Stock, par value $0.001 per share
2020-07-07$57.72/sh−2,450$141,405→ 10,499,904 total(indirect: See Footnotes) - Sale
Common Stock, par value $0.001 per share
2020-07-08$59.83/sh−60,018$3,590,799→ 10,344,922 total(indirect: See Footnotes) - Sale
Common Stock, par value $0.001 per share
2020-07-08$60.83/sh−13,401$815,167→ 10,331,521 total(indirect: See Footnotes) - Sale
Common Stock, par value $0.001 per share
2020-07-06$58.85/sh−18,486$1,087,979→ 10,522,733 total(indirect: See Footnotes) - Sale
Common Stock, par value $0.001 per share
2020-07-07$59.90/sh−20,147$1,206,705→ 10,422,967 total(indirect: See Footnotes) - Sale
Common Stock, par value $0.001 per share
2020-07-08$58.92/sh−18,027$1,062,216→ 10,404,940 total(indirect: See Footnotes) - Sale
Common Stock, par value $0.001 per share
2020-07-08$61.56/sh−8,554$526,564→ 10,322,967 total(indirect: See Footnotes)
Vifor Pharma Ltd.
10% Owner
Transactions
- Sale
Common Stock, par value $0.001 per share
2020-07-08$59.83/sh−60,018$3,590,799→ 10,344,922 total(indirect: See Footnotes) - Sale
Common Stock, par value $0.001 per share
2020-07-06$57.80/sh−47,825$2,764,118→ 10,541,219 total(indirect: See Footnotes) - Sale
Common Stock, par value $0.001 per share
2020-07-06$58.85/sh−18,486$1,087,979→ 10,522,733 total(indirect: See Footnotes) - Sale
Common Stock, par value $0.001 per share
2020-07-07$59.90/sh−20,147$1,206,705→ 10,422,967 total(indirect: See Footnotes) - Sale
Common Stock, par value $0.001 per share
2020-07-08$58.92/sh−18,027$1,062,216→ 10,404,940 total(indirect: See Footnotes) - Sale
Common Stock, par value $0.001 per share
2020-07-08$61.56/sh−8,554$526,564→ 10,322,967 total(indirect: See Footnotes) - Sale
Common Stock, par value $0.001 per share
2020-07-06$59.57/sh−20,379$1,214,024→ 10,502,354 total(indirect: See Footnotes) - Sale
Common Stock, par value $0.001 per share
2020-07-07$57.72/sh−2,450$141,405→ 10,499,904 total(indirect: See Footnotes) - Sale
Common Stock, par value $0.001 per share
2020-07-07$59.04/sh−56,790$3,352,728→ 10,443,114 total(indirect: See Footnotes) - Sale
Common Stock, par value $0.001 per share
2020-07-08$60.83/sh−13,401$815,167→ 10,331,521 total(indirect: See Footnotes)
Transactions
- Sale
Common Stock, par value $0.001 per share
2020-07-06$58.85/sh−18,486$1,087,979→ 10,522,733 total(indirect: See Footnotes) - Sale
Common Stock, par value $0.001 per share
2020-07-07$59.04/sh−56,790$3,352,728→ 10,443,114 total(indirect: See Footnotes) - Sale
Common Stock, par value $0.001 per share
2020-07-08$59.83/sh−60,018$3,590,799→ 10,344,922 total(indirect: See Footnotes) - Sale
Common Stock, par value $0.001 per share
2020-07-07$57.72/sh−2,450$141,405→ 10,499,904 total(indirect: See Footnotes) - Sale
Common Stock, par value $0.001 per share
2020-07-08$60.83/sh−13,401$815,167→ 10,331,521 total(indirect: See Footnotes) - Sale
Common Stock, par value $0.001 per share
2020-07-06$57.80/sh−47,825$2,764,118→ 10,541,219 total(indirect: See Footnotes) - Sale
Common Stock, par value $0.001 per share
2020-07-06$59.57/sh−20,379$1,214,024→ 10,502,354 total(indirect: See Footnotes) - Sale
Common Stock, par value $0.001 per share
2020-07-07$59.90/sh−20,147$1,206,705→ 10,422,967 total(indirect: See Footnotes) - Sale
Common Stock, par value $0.001 per share
2020-07-08$61.56/sh−8,554$526,564→ 10,322,967 total(indirect: See Footnotes) - Sale
Common Stock, par value $0.001 per share
2020-07-08$58.92/sh−18,027$1,062,216→ 10,404,940 total(indirect: See Footnotes)
Footnotes (14)
- [F1]In addition to Vifor (International) Ltd., an entity formed under the laws of Switzerland ("Vifor"), and Vifor Fresenius Medical Care Renal Pharma Ltd., an entity formed under the laws of Switzerland ("VFMCRP"), this Form 4 is being filed by Vifor Pharma Ltd., an entity formed under the laws of Switzerland ("Vifor Pharma" and, together with Vifor and VFMCRP, the "Reporting Persons"). The business addresses for each of the Reporting Persons are listed above. Each of the Reporting Persons may be deemed to have a pecuniary interest in securities reported by it on this Form 4 (the "Subject Securities").
- [F10]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.61 to $60.35, inclusive.
- [F11]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.29 to $59.28, inclusive.
- [F12]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.30 to $60.28, inclusive.
- [F13]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.30 to $61.23, inclusive.
- [F14]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.32 to $61.855, inclusive.
- [F2]Beneficial ownership of the common stock referred to herein is being reported solely because (i) Vifor Pharma may be deemed to beneficially own 6,989,634 shares of Common Stock of ChemoCentryx, Inc. as a result of Vifor Pharma's indirect ownership of 100% of the equity interests of Vifor, and (ii) Vifor Pharma may be deemed to beneficially own 3,333,333 shares of Common Stock of ChemoCentryx, Inc. as a result of Vifor Pharma's indirect ownership of 55% of the equity interests of VFMCRP.
- [F3]Each of the Reporting Persons disclaims any beneficial ownership of any of the Subject Securities, except to the extent of any pecuniary interest therein.
- [F4]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Vifor on June 26, 2020.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.28 to $58.26, inclusive. Vifor undertakes to provide ChemoCentryx, Inc., any security holder of ChemoCentryx, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5), (6) and (7) to this Form 4.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.29 to $59.28, inclusive.
- [F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.29 to $60.00, inclusive.
- [F8]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.08 to $58.06, inclusive.
- [F9]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.60 to $59.59, inclusive.
Documents
Issuer
ChemoCentryx, Inc.
CIK 0001340652
Entity typeother
IncorporatedSwitzerland
Related Parties
1- filerCIK 0001675217
Filing Metadata
- Form type
- 4
- Filed
- Jul 7, 8:00 PM ET
- Accepted
- Jul 8, 8:39 PM ET
- Size
- 29.3 KB